Recursion Pharmaceuticals
RXRX
4.27
-0.36
-7.78%
Recursion Pharmaceuticals
US · RXRX
#2649 by market cap
Listed 2021
4.27
-0.36
-7.78%
Live - 5344 symbols - heartbeat 177s ago
· 2026-10-08 08:29
Pre-market
4.21
-1.41%
After-hours
4.27
0.00%
Overnight
4.26
-0.23%
- Market cap
- 2.29B
- P/E (TTM)i
- -4.27
- P/Bi
- 2.50
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on RXRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.17, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +26.92% YoY
Margins
- Gross margin
- 4.45%
- Operating margin
- -872.83%
- Net margin
- -868.29%
Key ratios & quality
- Enterprise valuei
- 1.57B
- Altman Z-Scorei
- 1.17
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.32M | 3.96M | 10.18M | 39.84M | 44.58M | 58.84M | 74.68M |
| Gross profit | -- | 3.41M | 10.00M | -8.59M | 1.29M | 13.25M | 3.30M |
| Selling & admin expenses | 18.95M | 25.26M | 57.68M | 81.60M | 110.82M | 178.18M | 176.59M |
| Research & development | 45.81M | 63.32M | 135.27M | 155.70M | 241.23M | 314.42M | 475.27M |
| Operating profit | -62.44M | -84.62M | -182.78M | -245.73M | -350.06M | -479.00M | -648.13M |
| Pretax profit | -61.88M | -87.01M | -186.48M | -239.48M | -332.13M | -464.79M | -644.90M |
| Tax | -- | -- | 0 | 0 | -4.06M | -1.13M | -136.00K |
| Net profit | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M |
| Basic EPS | -1 | -1 | -1 | -1 | -2 | -2 | -1 |
| Diluted EPS | -0.55 | -0.77 | -1.49 | -1.36 | -1.58 | -1.69 | -1.44 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 14.75M | 19.22M | 5.18M | 35.54M | 6.47M | 7.67M |
| Gross profit | -7.01M | -1.06M | -9.70M | 21.08M | -6.19M | -4.19M |
| Selling & admin expenses | 54.65M | 46.65M | 41.63M | 33.66M | 34.59M | 41.53M |
| Research & development | 129.63M | 128.64M | 121.06M | 95.94M | 87.90M | 89.61M |
| Operating profit | -191.37M | -176.23M | -172.20M | -108.33M | -128.51M | -134.97M |
| Pretax profit | -202.65M | -171.90M | -162.25M | -108.10M | -122.11M | -131.01M |
| Tax | -158.00K | 0 | 3.00K | 20.00K | -4.60M | -1.00K |
| Net profit | -202.49M | -171.90M | -162.25M | -108.12M | -117.50M | -131.01M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.50 | -0.41 | -0.36 | -0.21 | -0.22 | -0.25 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 76.40M | 266.44M | 534.72M | 569.81M | 438.14M | 714.27M | 812.85M |
| Cash & ST investments | 69.88M | 262.13M | 516.56M | 549.91M | 391.57M | 594.35M | 743.29M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 101.43M | 298.59M | 610.35M | 701.29M | 653.70M | 1.45B | 1.47B |
| Total current liabilities | 6.68M | 23.10M | 46.66M | 100.27M | 93.17M | 187.47M | 147.71M |
| Short-term debt | 544.00K | 1.54M | 1.51M | 6.05M | 6.16M | 22.22M | 21.75M |
| Long-term debt | 12.42M | 11.41M | 633.00K | 536.00K | 1.10M | 19.02M | 9.56M |
| Total liabilities | 225,696,000.00 | 504,874,000.00 | 67,407,000.00 | 215,482,000.00 | 190,263,000.00 | 413,816,000.00 | 343,265,000.00 |
| Total equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B | 1.13B |
| Retained earnings | -126.60M | -213.60M | -400.08M | -639.56M | -967.62M | -1.43B | -2.08B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 584.15M | 587.16M | 714.11M | 812.85M | 709.56M | 603.46M |
| Cash & ST investments | 500.45M | 525.11M | 659.84M | 743.29M | 654.47M | 545.68M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.31B | 1.30B | 1.40B | 1.47B | 1.34B | 1.21B |
| Total current liabilities | 141.98M | 164.03M | 155.10M | 147.71M | 129.70M | 119.89M |
| Short-term debt | 20.44M | 20.48M | 20.44M | 21.75M | 22.35M | 22.69M |
| Long-term debt | 16.45M | 14.20M | 11.90M | 9.56M | 7.18M | 4.75M |
| Total liabilities | 371,287,000.00 | 383,209,000.00 | 352,578,000.00 | 343,265,000.00 | 314,753,000.00 | 297,665,000.00 |
| Total equity | 933.95M | 919.15M | 1.05B | 1.13B | 1.02B | 915.00M |
| Retained earnings | -1.63B | -1.81B | -1.97B | -2.08B | -2.19B | -2.32B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -57.04M | -45.40M | -158.61M | -83.52M | -287.78M | -359.17M | -371.81M |
| Depreciation & amortization | 2.49M | 3.94M | 8.41M | 11.76M | 24.40M | 36.49M | 83.70M |
| Free cash flow | -60.95M | -52.13M | -198.41M | -120.88M | -300.33M | -376.22M | -380.44M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 462.90M | 143.71M | 128.09M | 300.42M | 528.86M |
| Ending cash balance | 75.17M | 267.17M | 295.35M | 559.11M | 401.43M | 603.02M | 753.92M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -131.96M | -76.42M | -117.36M | -46.07M | -81.10M | -105.95M |
| Depreciation & amortization | 19.33M | 23.85M | 21.04M | 19.48M | 19.67M | 18.17M |
| Free cash flow | -133.79M | -81.73M | -117.60M | -47.32M | -81.44M | -107.91M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 41.02M | 100.00M | 254.46M | 133.38M | 0 | 0 |
| Ending cash balance | 509.16M | 533.85M | 667.15M | 753.92M | 665.18M | 556.82M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -110.79 | -46.56 | -69.12 | -61.90 | -59.54 |
| ROA %i | -61.01 | -43.50 | -41.03 | -36.52 | -48.42 | -44.11 | -44.12 |
| ROIC %i | -- | -- | -100.94 | -45.03 | -66.01 | -57.66 | -56.60 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -69.58 |
| EBIT margin %i | -3,579.43 | -2,509.41 | -1,835.27 | -603.36 | -756.75 | -791.98 | -866.04 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.43 | 11.53 | 11.46 | 5.68 | 4.70 | 3.81 | 5.50 |
| Quick ratioi | 10.48 | 11.35 | 11.27 | 5.51 | 4.24 | 3.43 | 5.20 |
| Debt / assetsi | 15.94 | 5.25 | 1.88 | 7.27 | 7.75 | 7.49 | 5.29 |
| LT debt / equityi | -- | -- | 1.84 | 9.25 | 9.61 | 8.34 | 4.97 |
| Interest coveragei | -96.45 | -62.98 | -62.17 | -4,353.11 | -3,423.00 | -294.67 | -355.30 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 185.17 | 134.26 | 80.17 | 23.23 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -86.10 | -86.34 | -91.06 | -59.54 | -57.16 | -56.58 |
| ROA %i | -61.70 | -62.47 | -67.31 | -44.12 | -42.33 | -41.26 |
| ROIC %i | -79.78 | -78.83 | -84.18 | -56.60 | -54.72 | -54.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -958.32 | -1,002.84 | -1,642.87 | -866.04 | -855.97 | -967.71 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.11 | 3.58 | 4.60 | 5.50 | 5.47 | 5.03 |
| Quick ratioi | 3.85 | 3.33 | 4.40 | 5.20 | 5.15 | 4.67 |
| Debt / assetsi | 7.12 | 6.76 | 5.89 | 5.29 | 5.40 | 5.50 |
| LT debt / equityi | 7.76 | 7.35 | 5.92 | 4.97 | 4.88 | 4.80 |
| Interest coveragei | -278.26 | -301.48 | -294.01 | -355.30 | -340.62 | -352.45 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 08:29:38 · For reference only, not investment advice and not tailored to your situation.